Nkarta Inc (NAS:NKTX)
$ 2.87 -0.12 (-4.01%) Market Cap: 202.53 Mil Enterprise Value: 4.93 Mil PE Ratio: 0 PB Ratio: 0.47 GF Score: 38/100

Nkarta Inc at Jefferies Healthcare Conference (Virtual) Transcript

Jun 02, 2021 / 07:30PM GMT
Release Date Price: $25.22 (+1.65%)
Dingding Shi
Jefferies LLC, Research Division - Equity Analyst

Good afternoon, everyone. My name is Kelly Shi, one of the biotech equity analysts at Jefferies. Thank you for attending our Virtual Healthcare Conference. We are very pleased to have Mr. Paul Hastings, President and CEO from Nkarta Therapeutics, join us today. He also brings his big team, Kanya, Ralph, Nadir, James and Greg.

And to start off, Paul, could you introduce your team and also the company for those who are less familiar with the Nkarta story?

Paul J. Hastings
Nkarta, Inc. - CEO, President & Director

Yes. Thank you, Kelly, for inviting us. And we're thrilled to be here. The beauty of Zoom is you have the whole team. So you can ask whatever questions you'd like, Kelly. And we will be happy to give you multiple points of view on that one question you ask. So the team here, we have James, our CSO, Chief Scientific Officer; Kanya Rajangam is our Chief Medical Officer. Nadir Mahmood is our Chief Financial and Business Officer. And Ralph Brandenberger is our Senior VP of Tech Ops

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot